Safety, Tolerability and Pharmacokinetics of Multiple Rising Inhaled Doses of BI 1265162 in Healthy Male Subjects in a Randomised, Double Blind, Placebo-controlled Trial
Phase of Trial: Phase I
Latest Information Update: 17 Dec 2018
Price : $35 *
At a glance
- Drugs BI 1265162 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 07 Dec 2018 Status changed from active, no longer recruiting to completed.
- 28 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 01 Oct 2018 Planned End Date changed from 9 Nov 2018 to 6 Dec 2018.